The UK diabetes drugs market is experiencing steady growth (CAGR 3.05%), driven by rising prevalence and innovative therapies. This comprehensive analysis explores market size, key segments (insulin, GLP-1 agonists, SGLT-2 inhibitors), leading companies (Novo Nordisk, Sanofi, Eli Lilly), and future trends impacting this £1.06 billion market (2025).
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.